ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
August 04, 2020Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).1 -
TB Alliance, Mylan Announce Collaboration to Commercialize Pretomanid
April 19, 2019Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).
Pharma Sources Insight January 2025
